The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic score for second-line chemotherapy of advanced non-small cell lung cancer (NSCLC): External validation in a phase III trial comparing vinflunine with docetaxel.
M. J. Krzakowski
No relevant relationships to disclose
M. Di Maio
No relevant relationships to disclose
K. Perraud
No relevant relationships to disclose
D. M. Kowalski
No relevant relationships to disclose
C. Gridelli
No relevant relationships to disclose